Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.

By Christy Santhosh Oct 19 (Reuters) - German drugmaker Merck KGaA said on Monday it would acquire UK-based Silence ...

Merck⁠ officially introduced a $500 million, 120,000-square-foot research building featuring automated robotics systems and ...

The 130-year-old drugmaker is using Proto’s life-size displays and AI avatars to bring disease-awareness campaigns to ...

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...

Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 ...

With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Dawn Health, and German science and tech firm Merck KGaA are collaborating to create a model for patient support programs, the latter said Wednesday. Merck KGaA said the companies intend to combine ...

Germany’s Merck KGaA has agreed to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion ...

The acquisition will add a Phase III-ready siRNA therapy for polycythaemia vera to Merck’s rare disease pipeline, ...